Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Studie, für die rekrutiert wird"

Recruiting

Studien-Nr. CA230-1019  |   NCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Zusammenfassung

  • Phase 1/Phase 2
  • Symbol für männliches und weibliches Geschlecht
  • 18+
    Altersgruppe
  • 16
    Standorte
  • BMS-Symbol für "Studie, für die rekrutiert wird"
    Recruiting

Überblick

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

Druckmedium-alt Druckmedium
email E-Mail

Nächstgelegenes Prüfzentrum

Wichtigste Einschlusskriterien

Einschlusskriterien

Symbol für Einschlusskriterien img
  • Cohort A.
    1. Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU/L or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
      1. Body mass index (BMI) of 18.0 to 32.0 kg/m^2, inclusive. BMI = weight (kg)/ (height [m])^2 as measured at screening.
        1. No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.
        2. Cohort B.
          1. Participants with a documented diagnosis of Sickle Cell Disease (SCD) with genotype HbSS, HbSβ0-thal, or HbSβ+-thal.
            1. Participants with ≥ 4 vaso-occlusive crises (VOCs) within the previous 12 months or ≥ 2 VOCs within the previous 6 months.
              1. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
                1. Must have the following laboratory values:.
                  1. Hemoglobin ≥ 5.5 and ≤ 12 g/dL (males) or ≥ 5.5 and ≤ 10.6 g/dL (females).
                  2. Absolute neutrophil count ≥ 1500/μL.
                  3. Platelet count ≥ 100 × 10^3/μL.
                  4. Absolute reticulocyte count > 100 × 10^3/μL or > 50 × 10^3/μL if taking hydroxyurea.

              Ausschlusskriterien

              Symbol für Ausschlusskriterien
              • Cohort A.
                1. Any significant medical condition or any condition that confounds the ability to interpret data from the study.
                  1. Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.
                    1. Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.
                    2. Cohort B.
                      1. Participants with any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
                        1. Participants with more than 6 severe VOCs defined as VOCs requiring ≥ 24 hours of hospital admission within 12 months prior to the first dose of study intervention or any VOC requiring ≥ 24 hours of hospital admission within 30 days prior to the first dose of study intervention.
                          1. Participants with any episode of acute chest syndrome within the last 6 months prior to the first dose of study intervention.
                            1. Creatinine clearance (CrCl) < 60 mL/min/1.72m2 using Chronic Kidney Disease Epidemiology (CKD-EPI) equation
                            2. Cohort A and B.
                              1. Participant is receiving regularly scheduled RBC or platelet transfusions or has received a RBC transfusion within 28 days and a platelet transfusion within 14 days prior to starting treatment with BMS-986470.
                              Zusätzliche Informationen*
                              • Other protocol-defined Inclusion/Exclusion criteria apply.

                                Behandlungsmöglichkeiten

                                Studienarme

                                ZUGEWIESENE BEHANDLUNG

                                Studienarme

                                Experimental: Cohort A Part 1

                                ZUGEWIESENE BEHANDLUNG
                                • Drug: BMS-986470, Placebo

                                Studienarme

                                Experimental: Cohort A Part 2

                                ZUGEWIESENE BEHANDLUNG
                                • Drug: BMS-986470, Placebo

                                Studienarme

                                Experimental: Cohort A Part 3

                                ZUGEWIESENE BEHANDLUNG
                                • Drug: BMS-986470, Famotidine

                                Studienarme

                                Experimental: Cohort B Part 1

                                ZUGEWIESENE BEHANDLUNG
                                • Drug: BMS-986470, Placebo

                                Studienarme

                                Experimental: Cohort B Part 2

                                ZUGEWIESENE BEHANDLUNG
                                • Drug: BMS-986470
                                Prüfen Sie, ob eine der klinischen Studien für Sie infrage kommt
                                Kommt die Studie für Sie infrage
                                Beantworten Sie einige Fragen zu Ihrer Gesundheit, um festzustellen, ob diese Studie für Sie infrage kommt
                                Geeignete Studie
                                Wenn ihnen eine passende Studie angezeigt wird, klicken Sie auf die Studie, damit Sie die Liste der Prüfzentren angezeigt bekommen.
                                Wählen Sie einen Prüfzentrumsstandort aus
                                Wählen Sie einen Prüfzentrumsstandort aus, der für Sie günstig ist
                                Registrieren
                                Geben Sie Ihre Kontaktdaten ein, damit das Prüfzentrum mit Ihnen Kontakt aufnehmen kann.

                                Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!